相关实验视频

Updated: Jul 26, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

在高级软组织肉瘤中第二和第三线治疗的有效性:现实研究

Laura Gutierrez-Sainz¹, Sara Martinez-Fdez², Jorge Pedregosa-Barbas²

¹Department of Medical Oncology, La Paz University Hospital-Institute for Health Research (IdiPAZ), Paseo de la Castellana 261, 28046, Madrid, Spain. laura.gutierrezsainz@gmail.com.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

|June 17, 2023

概括

对于高级软组织肉瘤 (STS) 的第二线和第三线治疗也显示出类似的疗效. 然而,特定的化疗方案在某些STS亚型中表现出显著的活性,这表明高级STS的个性化治疗方法.

科学领域:

在瘤学瘤学.
医学研究医学研究

背景情况:

软组织肉瘤 (STS) 是一种罕见且多样化的瘤.
已建立的第二线 (2L) 和第三线 (3L) 治疗先进的STS存在.
增长调节指数 (GMI) 是一种探索性指标,用于在患者内进行药物疗效比较.

研究的目的:

评估2L和3L治疗对先进的STS的实际有效性.
分析顺序性STS治疗的进展时间 (TTP) 和GMI.
根据STS基因型识别特定的疗法活动.

主要方法:

对接受至少两种治疗线 (2010-2020年) 的高级STS患者的回顾性分析.
计算TTP和GMI (连续治疗之间的TTP比率).
对不同疗法和组织型的治疗疗效进行比较.

主要成果:

2L和3L治疗的TTP中位数分别为3.16和3.06个月 (GMI中位数:0.81和0.74).
特拉贝克德丁,格姆西塔-达卡巴,格姆西塔-多克塞尔,帕佐帕尼布和伊福斯法米德是常见的治疗方案.
格姆西塔-达卡巴辛在未分化的多形肉瘤 (UPS) 和性肉瘤 (leiomyosarcoma) 中表现出活性;在UPS中表现出帕索巴尼布;在突肉瘤中表现出 ifosfamide.

结论:

通常使用的2L和3L STS疗法在这个队列中表现出可比的疗效.
在某些疗法中观察到显著的组织型特异性活性.
基于STS亚型的个性化治疗策略可能会改善结果.

关键词:

增长调节指数增长调节指数现实世界的研究研究.第二线的第二线.软组织肉瘤 (软组织肉瘤)第三线的第三线.

更多相关视频

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...